Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Q32 Bio (QTTB) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Q32 Bio (QTTB) over the last 9 years, with Q3 2025 value amounting to $49.0 million.

  • Q32 Bio's Cash & Equivalents fell 4494.82% to $49.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.0 million, marking a year-over-year decrease of 4494.82%. This contributed to the annual value of $78.0 million for FY2024, which is 20434.87% up from last year.
  • According to the latest figures from Q3 2025, Q32 Bio's Cash & Equivalents is $49.0 million, which was down 4494.82% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Q32 Bio's Cash & Equivalents ranged from a high of $248.1 million in Q1 2022 and a low of $20.1 million during Q2 2023
  • In the last 5 years, Q32 Bio's Cash & Equivalents had a median value of $78.0 million in 2024 and averaged $84.0 million.
  • In the last 5 years, Q32 Bio's Cash & Equivalents tumbled by 8861.67% in 2023 and then soared by 38694.16% in 2024.
  • Q32 Bio's Cash & Equivalents (Quarter) stood at $110.3 million in 2021, then tumbled by 69.2% to $34.0 million in 2022, then dropped by 24.62% to $25.6 million in 2023, then skyrocketed by 204.35% to $78.0 million in 2024, then crashed by 37.1% to $49.0 million in 2025.
  • Its Cash & Equivalents stands at $49.0 million for Q3 2025, versus $54.8 million for Q2 2025 and $65.5 million for Q1 2025.